Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) priced an underwritten public offering of 32,500,001 common shares at $6.00 per share and pre-funded warrants for 833,333 shares at $5.999 each. Expected gross proceeds are about $200 million, excluding any underwriter option exercise.

The company granted underwriters a 30-day option for up to 5,000,000 additional shares. Closing is expected on or about June 26, 2026, subject to customary conditions.

Positive

• Equity offering expected to raise approximately $200 million in gross proceeds
• Underwriters granted 30-day option for up to 5,000,000 additional shares

Negative

• Issuance of 32,500,001 new shares plus potential 5,000,000 more increases share count and dilutes existing holders

News Market Reaction – TSHA

-10.52%

4 alerts

-10.52% Session close to close

-6.9% Trough Tracked

$1.99B Market Cap

0.1x Rel. Volume

In the Jun 25 session, TSHA declined 10.52%, reflecting a significant negative market reaction. Argus tracked a trough of -6.9% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.5% in the session following this news. A negative reaction despite positive cl...

Analysis

The stock dropped -10.5% in the session following this news. A negative reaction despite positive clinical momentum fits TSHA’s history of volatile responses to offerings. Elevated short interest and recent insider net selling may amplify downside if investors focus on dilution and financing over long-term catalysts.

Key Figures

Common shares offered: 32,500,001 shares Offering price: $6.00 per share Pre-funded warrant shares: 833,333 shares +3 more

6 metrics

Common shares offered 32,500,001 shares Underwritten public offering

Offering price $6.00 per share Public offering of common stock

Pre-funded warrant shares 833,333 shares Pre-funded warrants in lieu of common stock

Pre-funded warrant price $5.999 per warrant Offering price before underwriting discounts

Underwriters’ option 5,000,000 shares 30-day option to purchase additional common stock

Gross proceeds $200.0 million Expected before discounts, commissions and expenses

Previous Offering Reports

4 past events · Latest: May 28 (Neutral)

Same Type Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
May 28	Equity offering pricing	Neutral	+12.7%	Pricing of large equity and pre-funded warrant raise around $200M.
May 28	Offering announcement	Neutral	+12.7%	Announcement of proposed public equity and pre-funded warrant offering.
Jun 26	Equity offering pricing	Neutral	-17.2%	Pricing of $75M common stock and pre-funded warrant financing.
Jun 25	Offering announcement	Neutral	-17.2%	Announcement of planned $75M equity and pre-funded warrant raise.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Offering-related headlines have produced mixed reactions, with both sharp rallies and selloffs around capital raises.

Key Terms

pre-funded warrants, underwritten public offering, shelf registration statement, prospectus supplement

4 terms

pre-funded warrants financial

"pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"A shelf registration statement relating to the securities offered in the public offering described above was filed"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Jefferies, Goldman Sachs & Co. LLC, Piper Sandler and Cantor are acting as joint book-running managers for the proposed offering. Baird is acting as lead manager for the proposed offering.

A shelf registration statement relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the SEC) on November 4, 2025, and became automatically effective upon filing. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, or by email at prospectus@psc.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha’s research, development and regulatory plans for its product candidates and Taysha’s public offering, including expected gross proceeds and anticipated closing date, the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha’s business are described in detail in its SEC filings, including in Taysha’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which is available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

FAQ

What did Taysha Gene Therapies (TSHA) announce about its June 2026 stock offering?

Taysha Gene Therapies announced pricing of an underwritten public offering of common stock and pre-funded warrants. According to Taysha, the deal includes 32,500,001 common shares and 833,333 pre-funded warrants, targeting about $200 million in gross proceeds before fees and expenses.

How large is the TSHA common stock and pre-funded warrant offering and what are the prices?

The offering totals 32,500,001 common shares at $6.00 and 833,333 pre-funded warrants at $5.999. According to Taysha, these securities are offered before underwriting discounts and commissions, with expected gross proceeds of approximately $200 million, excluding any underwriter option exercise.

When is the closing date for the Taysha Gene Therapies (TSHA) June 2026 public offering?

The offering is expected to close on or about June 26, 2026. According to Taysha, completion of the transaction remains subject to customary closing conditions that typically apply to underwritten public offerings in the U.S. capital markets.

What is the underwriters’ 30-day option in the TSHA June 2026 stock offering?

Underwriters received a 30-day option to buy up to 5,000,000 additional TSHA common shares. According to Taysha, these shares would be sold at the public offering price of $6.00 per share, less underwriting discounts and commissions, potentially increasing total gross proceeds.

Who are the underwriters for the Taysha Gene Therapies (TSHA) June 2026 equity offering?

Jefferies, Goldman Sachs, Piper Sandler and Cantor are joint book-running managers, with Baird as lead manager. According to Taysha, these firms are managing the underwritten public offering of TSHA common stock and pre-funded warrants under an effective shelf registration statement.

How might the June 2026 TSHA stock offering affect existing shareholders?

The transaction increases the company’s outstanding share count, which typically dilutes existing holders’ ownership percentages. According to Taysha, 32,500,001 new shares are offered, with an additional 5,000,000 shares potentially issuable under the underwriters’ 30-day option.

Where can investors find the prospectus for the Taysha Gene Therapies (TSHA) June 2026 offering?

Investors can access the preliminary prospectus supplement and accompanying prospectus on the SEC’s website at www.sec.gov. According to Taysha, a final prospectus supplement will also be filed and can be requested from the joint book-running managers’ prospectus departments.